Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

(2011) Richard H. Haubrich et al.   AIDS

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients

(2011) Brian Gazzard et al.   AIDS

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients

(2011) Joseph Gathe et al.   ANTIVIRAL THERAPY

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial

(2011) Vicente Soriano et al.   ANTIVIRAL THERAPY

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

(2011) Paul E. Sax et al.   JOURNAL OF INFECTIOUS DISEASES

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Does earlier HIV RNA suppression provide long-term benefits?

(2010) Graeme Moyle et al.   AIDS

Short Communication: Comparable Safety and Efficacy with Once-Daily Versus Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of the Randomized Trial M05-730

(2010) Juan González-García et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study

(2010) Rebekah L. Puls et al.   CLINICAL INFECTIOUS DISEASES

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

(2010) Frank A Post et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

(2010) R Qaqish et al.   Journal of the International AIDS Society

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

(2009) D. R (Niel) Malan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Designing and interpreting HIV noninferiority trials in naive and experienced patients

(2008) Andrew Hill et al.   AIDS

Emergence of Drug Resistance in HIV Type 1–Infected Patients after Receipt of First‐Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials

(2008) Ravindra Gupta et al.   CLINICAL INFECTIOUS DISEASES

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

(2008) Richard Elion et al.   HIV CLINICAL TRIALS

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

(2008) Kimberly Y Smith et al.   AIDS Research and Therapy